<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Rheumatol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Rheumatol</journal-id><journal-title-group><journal-title>BMC Rheumatology</journal-title></journal-title-group><issn pub-type="epub">2520-1026</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40400044</article-id><article-id pub-id-type="pmc">PMC12093799</article-id><article-id pub-id-type="publisher-id">509</article-id><article-id pub-id-type="doi">10.1186/s41927-025-00509-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Association of matrix metalloproteinase 7 and the alpha-chain of fibrinogen at baseline with response to methotrexate at 3 months in patients with early rheumatoid arthritis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hambardzumyan</surname><given-names>Karen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hamsten</surname><given-names>Carl</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lourido</surname><given-names>Luc&#x000ed;a</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Saevarsdottir</surname><given-names>Saedis</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Nilsson</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>van Vollenhoven</surname><given-names>Ronald F.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Jakobsson</surname><given-names>Per-Johan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Idborg</surname><given-names>Helena</given-names></name><address><email>helena.idborg@ki.se</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00m8d6786</institution-id><institution-id institution-id-type="GRID">grid.24381.3c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9241 5705</institution-id><institution>Division of Rheumatology, Department of Medicine, Center for Molecular Medicine, </institution><institution>Karolinska Institutet, Karolinska University Hospital, Karolinska University Hospital, </institution></institution-wrap>Solna, Stockholm, SE-17176 Sweden </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/056d84691</institution-id><institution-id institution-id-type="GRID">grid.4714.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0626</institution-id><institution>Unit of Immunology and Allergy, Department of Medicine, </institution><institution>Karolinska Institutet and Karolinska University Hospital, </institution></institution-wrap>Stockholm, Sweden </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04c9g9234</institution-id><institution-id institution-id-type="GRID">grid.488921.e</institution-id><institution>Grupo de Investigaci&#x000f3;n de Reumatolog&#x000ed;a (GIR) - Unidad de Prote&#x000f3;mica, </institution><institution>Instituto de Investigaci&#x000f3;n Biom&#x000e9;dica de A Coru&#x000f1;a (INIBIC), Complexo Hospitalario Universitario de A Coru&#x000f1;a (CHUAC), </institution></institution-wrap>Sergas, A Coru&#x000f1;a, Spain </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/056d84691</institution-id><institution-id institution-id-type="GRID">grid.4714.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0626</institution-id><institution>Division of Clinical Epidemiology, Department of Medicine Solna, </institution><institution>Karolinska Institutet, </institution></institution-wrap>Stockholm, Sweden </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01db6h964</institution-id><institution-id institution-id-type="GRID">grid.14013.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 0640 0021</institution-id><institution>Faculty of Medicine, School of Health Sciences, </institution><institution>University of Iceland, </institution></institution-wrap>Reykjavik, Iceland </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/026vcq606</institution-id><institution-id institution-id-type="GRID">grid.5037.1</institution-id><institution-id institution-id-type="ISNI">0000000121581746</institution-id><institution>Affinity Proteomics, SciLifeLab, School of Biotechnology, </institution><institution>KTH &#x02013; Royal Institute of Technology, </institution></institution-wrap>Stockholm, Sweden </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00q6h8f30</institution-id><institution-id institution-id-type="GRID">grid.16872.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0435 165X</institution-id><institution>Amsterdam Rheumatology and Immunology Center, </institution></institution-wrap>Amsterdam, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>9</volume><elocation-id>56</elocation-id><history><date date-type="received"><day>13</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>5</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">The identification of responders to methotrexate (MTX) would optimize the therapy of patients with early rheumatoid arthritis (eRA). Our aim was to identify protein biomarkers for the prediction of the response to MTX.</p></sec><sec><title>Methods</title><p id="Par2">We analysed patients with eRA (<italic>N</italic>&#x02009;=&#x02009;135) from the Swedish Pharmacotherapy (SWEFOT) trial population (Trial registration number: NCT00764725). Baseline serum levels of 177 proteins with an inflammatory signature were profiled via 380 antibodies in a suspension bead array format. Protein levels were analysed for their associations with the achievement of a low 28-joint disease activity score (LDA&#x02009;=&#x02009;DAS28&#x02009;&#x02264;&#x02009;3.2) after 3 months of MTX therapy (primary outcome) or a good response according to the European Alliance of Associations for Rheumatology (EULAR) criteria (secondary outcome).</p></sec><sec><title>Results</title><p id="Par3">Multivariable analysis revealed that the serum levels of two of the 177 proteins at baseline, matrix metalloproteinase 7 (MMP-7) and the alpha-chain of fibrinogen (FGA), were significantly different between patients who did and did not achieve LDA at 3 months. Among patients with low versus high levels of either MMP-7 or FGA, 60% versus 24% and 58% versus 22%, respectively, achieved LDA (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). Among patients with low levels of both proteins, 79% achieved LDA at 3 months, whereas only 18% of those with high levels of both proteins achieved LDA at 3 months (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). The results were similar when a secondary outcome was used.</p></sec><sec><title>Conclusions</title><p id="Par4">Low levels of MMP-7 and FGA at baseline were associated with improved clinical outcomes in eRA patients. Validation of these results in another eRA cohort is now warranted, and if confirmed, it may facilitate clinical decision-making regarding whether to start with MTX in monotherapy or more potent alternatives.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s41927-025-00509-8.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Rheumatoid arthritis</kwd><kwd>Biomarkers</kwd><kwd>Prediction</kwd><kwd>Affinity proteomics</kwd><kwd>Methotrexate therapy</kwd><kwd>Clinical response</kwd></kwd-group><funding-group><award-group><funding-source><institution>Karolinska Institute</institution></funding-source></award-group><open-access><p>Open access funding provided by Karolinska Institute.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects joints [<xref ref-type="bibr" rid="CR1">1</xref>]. Methotrexate (MTX), among the available disease-modifying antirheumatic drugs (DMARDs), is the standard first choice for the treatment of patients with early rheumatoid arthritis (eRA) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. However, only 30&#x02013;40% of RA patients on MTX achieve low disease activity [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Predictive measures would be much appreciated in clinical practice to identify responders/nonresponders to MTX therapy, making it possible to modify treatment at an earlier stage and limiting persistent disease activity and the risk of long-term disability.</p><p id="Par6">Previous studies have evaluated predictive factors for the response to MTX, some with consistent results and some with controversial results. For example, among demographic factors, female sex, younger age and current smoking status have been shown by many studies, including the Swedish Farmacotherapy (SWEFOT) trial, to be predictors of poor response to MTX [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. For protein biomarkers as predictors of MTX efficacy, the data are less consistent. For example, some studies, including SWEFOT, could not demonstrate any predictive value of autoantibodies for subsequent response to MTX [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. In contrast, in the PROMPT trial, anti-CCP positivity was associated with improved clinical outcomes [<xref ref-type="bibr" rid="CR9">9</xref>]. Potential biomarkers for the response to MTX therapy have recently been reviewed [<xref ref-type="bibr" rid="CR10">10</xref>], but have not been validated and implemented in clinical practice [<xref ref-type="bibr" rid="CR11">11</xref>]. </p><p id="Par7">In the present study, we investigated a panel of 177 proteins with an inflammatory signature for the prediction of the response to MTX in eRA patients from the SWEFOT trial.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec2344"><title>Patient population</title><p id="Par8">The SWEFOT trial (Trial registration number: NCT00764725, Study start 2002-12, Study completion 2008-12, <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/">https://www.clinicaltrials.gov/</ext-link>) has been initiated to compare treatment efficacy between a combination of conventional synthetic DMARD therapy (triple therapy) and biological therapy in MTX-inadequate responders [<xref ref-type="bibr" rid="CR4">4</xref>]. The trial was conducted in accordance with the Declaration of Helsinki and was approved by the regional ethics committee. All patients provided written informed consent before enrolment in the trial.</p><p id="Par9">Among the 493 DMARD-na&#x000ef;ve, clinically active (28-joint disease activity score [DAS28]&#x02009;&#x0003e;&#x02009;3.2) eRA patients recruited for the SWEFOT trial, 135 patients were analysed at baseline, 85 of whom did not achieve low disease activity (LDA&#x02009;=&#x02009;DAS28&#x02009;&#x02264;&#x02009;3.2) after 3 months of MTX monotherapy. The 135 patients were randomly selected, and then the selection was adjusted with the aim of achieving an even distribution of autoantibody positivity among men and women, since rheumatoid factor (RF) positivity might influence the detection of certain proteins. With this type of selection, it is possible to evaluate if a potential biomarker is relevant only in RF-positive or RF-negative patients. However, the selection will not be representative of the SWEFOT cohort since the proportion of RF-positive patients will be greater in the selection cohort, and RF positivity is associated with more severe disease.</p><p id="Par10">The primary outcome was the achievement of LDA after 3 months of MTX monotherapy. The secondary outcome was a good response based on the European Alliance of Associations for Rheumatology (EULAR) criteria [<xref ref-type="bibr" rid="CR12">12</xref>]. </p></sec><sec id="Sec332"><title>Suspension bead arrays</title><p id="Par11">Target proteins were selected based on a combination of literature review and expert input, focusing on those proteins previously associated with rheumatoid arthritis and inflammatory pathways. A total of 380 antibodies covering 177 target proteins were obtained from the Human Protein Atlas (Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>) and were immobilized on color-coded magnetic beads as previously described [<xref ref-type="bibr" rid="CR13">13</xref>]. Four quality controls were included; antihuman IgG (Jackson ImmunoResearch) and antialbumin (Dako) were used as positive controls, and rabbit IgG from nonimmunized rabbits (Bethyl) and bead identity with no proteins immobilized were used as negative controls. All the serum samples were randomized into 96-well plates, diluted 1:10 and labelled with biotin as previously described [<xref ref-type="bibr" rid="CR14">14</xref>]. Proteins were detected by incubation with a streptavidin-conjugated fluorophore followed by readout in a FlexMap3D instrument (Luminex Corp.). Proteins with missing data&#x02009;&#x0003e;&#x02009;20% in a subgroup were excluded from the analysis. The results are reported as the median fluorescent intensity (MFI) per bead identity and sample, and no further preprocessing of data, e.g., transformation or centering, was performed before further data analysis.</p></sec><sec id="Sec233344"><title>Statistical analysis</title><p id="Par12">The levels of the 177 target proteins for the 380 antibodies at baseline were compared between patients who achieved LDA and those who did not achieve LDA after 3 months of MTX monotherapy via the Mann&#x02012;Whitney U test. For eight proteins, p values&#x02009;&#x0003c;&#x02009;0.001 were obtained. After applying the Bonferroni correction, these proteins were not considered to differ significantly (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.0001). The Bonferroni-adjusted significance threshold is 0.05 / 380&#x02009;=&#x02009;0.00013. If a less stringent approach, such as the Benjamini-Hochberg correction, had been applied, the significance cut-off for the 8th-ranked protein would have been approximately 0.00105. However, although these eight proteins did not reach statistical significance in the univariate analysis after Bonferroni correction, they were considered potential candidates for biomarkers and were subsequently analysed in a multivariable logistic regression model. The univariate analysis was only used to select factors/proteins to be included in the regression model, and only independent predictors (<italic>n</italic>&#x02009;=&#x02009;2 of the 8 candidate proteins) were chosen for further analysis. The logistic regression model was only adjusted for age and sex as potential confounders. RF-positivity was adjusted for by means of the correction of the selection of patients. The independent predictors were analysed via receiver operating characteristic (ROC) curve analysis to define the area under the curve (AUC) and cut-off, which was based on the highest sum of sensitivity with specificity. Using the generated cut-offs, the patients were dichotomized, and the proportions of patients who achieved LDA or EULAR good response were compared between the groups via the chi-square test. Statistical analyses were performed via IBM SPSS version 24.</p></sec></sec><sec id="Sec3"><title>Results</title><sec id="Sec23122"><title>Patient characteristics and protein levels at baseline</title><p id="Par13">Among the 135 patients included in this study, compared with the remaining 358 patients from the SWEFOT trial, four baseline parameters (RF positivity, ESR, CRP and pain VAS) differed significantly (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>), but the group was otherwise representative of the trial as a whole.</p><p id="Par14">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics and demographic data of patients from the SWEFOT trial</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Baseline<break/>Characteristics<sup>a</sup></th><th align="left">Patients not<break/>analysed by<break/>AP (<italic>N</italic>&#x02009;=&#x02009;358)<sup>b</sup></th><th align="left">Patients<break/>analysed by<break/>AP (<italic>N</italic>&#x02009;=&#x02009;135)<sup>c</sup></th><th align="left"><italic>P</italic>-<break/>value<sup>d</sup></th></tr></thead><tbody><tr><td align="left">Female: N (%)</td><td align="left">246 (69)</td><td align="left">101 (75)</td><td align="left">0.186</td></tr><tr><td align="left">Age (years)</td><td align="left">57 (46&#x02013;64)</td><td align="left">57 (45&#x02013;65)</td><td align="left">0.860</td></tr><tr><td align="left">Current Smokers: N (%)</td><td align="left">61 (26)</td><td align="left">26 (22)</td><td align="left">0.363</td></tr><tr><td align="left">Symptom Duration (months)</td><td align="left">5 (3&#x02013;8)</td><td align="left">5 (4&#x02013;8)</td><td align="left">0.991</td></tr><tr><td align="left">Anti-CCP-positive: N (%)</td><td align="left">197 (66)</td><td align="left">79 (58)</td><td align="left">0.128</td></tr><tr><td align="left">RF-positive: N (%)</td><td align="left">256 (72)</td><td align="left">78 (58)</td><td align="left">
<bold>0.002</bold>
</td></tr><tr><td align="left">28 Swollen Joint Count</td><td align="left">10 (7&#x02013;14)</td><td align="left">10 (6&#x02013;15)</td><td align="left">0.936</td></tr><tr><td align="left">28 Tender Joint Count</td><td align="left">9 (5&#x02013;13)</td><td align="left">9 (5&#x02013;13)</td><td align="left">0.995</td></tr><tr><td align="left">ESR (mm/h)</td><td align="left">35 (22&#x02013;56)</td><td align="left">31 (17&#x02013;47)</td><td align="left">
<bold>0.019</bold>
</td></tr><tr><td align="left">CRP Level (mg/L)</td><td align="left">21 (9&#x02013;47)</td><td align="left">15 (8&#x02013;35)</td><td align="left">
<bold>0.014</bold>
</td></tr><tr><td align="left">PatG (VAS 0&#x02013;100&#x000a0;mm) Score</td><td align="left">59 (40&#x02013;75)</td><td align="left">56 (35&#x02013;72)</td><td align="left">0.156</td></tr><tr><td align="left">Pain VAS</td><td align="left">59 (42&#x02013;73)</td><td align="left">52 (38&#x02013;68)</td><td align="left">
<bold>0.038</bold>
</td></tr><tr><td align="left">HAQ</td><td align="left">1.13 (0.82&#x02013;1.63)</td><td align="left">1.0 (0.75&#x02013;1.50)</td><td align="left">0.074</td></tr><tr><td align="left">DAS28</td><td align="left">5.8 (5.1&#x02013;6.4)</td><td align="left">5.6 (4.9&#x02013;6.3)</td><td align="left">0.104</td></tr></tbody></table><table-wrap-foot><p>AP &#x02013; affinity proteomics, IQR &#x02013; interquartile range, anti-CCP - anti-cyclic citrullinated peptide, RF &#x02013; rheumatoid factor, ESR &#x02013; erythrocyte sedimentation rate, CRP &#x02013; C-reactive protein, PatG &#x02013; Patient&#x02019;s Global Assessment of Disease Activity, VAS &#x02013; visual analogue scale, HAQ &#x02013; health assessment questionnaire, DAS &#x02013; disease activity score</p><p><sup>a</sup> Data are presented in median (IQR), unless otherwise mentioned; <sup>b</sup> Number of patients whose information is missing for &#x0201c;Patients not included&#x0201d; column: Current Smokers (<italic>n</italic>&#x02009;=&#x02009;124), Anti-CCP (<italic>n</italic>&#x02009;=&#x02009;60), RF and HAQ (<italic>n</italic>&#x02009;=&#x02009;5), Swollen and Tender joint count (<italic>n</italic>&#x02009;=&#x02009;2), ESR (<italic>n</italic>&#x02009;=&#x02009;4), CRP, PatG VAS and Pain VAS (<italic>n</italic>&#x02009;=&#x02009;3) and DAS28 (<italic>n</italic>&#x02009;=&#x02009;7); <sup>c</sup> Number of patients whose information is missing for &#x0201c;Analysed Patients&#x0201d; column: Current Smokers (<italic>n</italic>&#x02009;=&#x02009;15), ESR, PatG VAS, Pain VAS and HAQ (<italic>n</italic>&#x02009;=&#x02009;1); DAS28 (<italic>n</italic>&#x02009;=&#x02009;2); <sup>d</sup> p-value represent probability of null hypothesis being correct for Mann-Whitney U test (for continues variables) or Chi-squared test (for categorical variables)</p></table-wrap-foot></table-wrap>
</p><p id="Par15">After adjustment for multiple testing (Bonferroni correction, <italic>p</italic>&#x02009;=&#x02009;0.05/380 tests&#x02009;=&#x02009;0.0001), no serum proteins differed significantly between patient groups who achieved (<italic>N</italic>&#x02009;=&#x02009;50) and did not achieve (<italic>N</italic>&#x02009;=&#x02009;85) LDA at 3 months. A threshold of <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 was used for a more generous selection of potential candidates for prediction for further multivariable analysis. Among the 177 serum proteins, the baseline levels of the following proteins differed between the two groups (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001): interferon regulatory factor 8 (IRF8), C-C motif chemokine ligand 11 (CCL11), interleukin-17B receptor (IL-17RB), regulator of G-protein signalling (RGS18), oxidized low-density lipoprotein receptor 1 (OLR1), matrix metalloproteinase 7 (MMP-7), &#x003b1;-chain of fibrinogen (FGA) and complement component 8 &#x003b3;-subunit (C8G) (Supplementary Figure <xref rid="MOESM1" ref-type="media">S1</xref>).</p><p id="Par16">For the detection of most of the target proteins, more than one antibody was used (177 proteins targeted by 380 antibodies) (Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>). Three antibodies against MMP-7 and two antibodies against FGA had correlation coefficients of 0.64 and 0.74, respectively.</p></sec><sec id="Sec23111"><title>Associations of baseline categories of MMP-7 and FGA with clinical outcome at 3 months</title><p id="Par17">In stepwise multivariable logistic regression analysis of the 8 proteins mentioned above, low baseline levels of MMP-7 and FGA were independently associated with the achievement of LDA after 3 months of MTX monotherapy, and continuous values of MMP-7 and FGA at baseline were analysed by ROC curve analysis, revealing AUCs of 0.692 (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, 95% CI: 0.601&#x02013;0.783) and 0.699 (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, 95% CI: 0.606&#x02013;0.792), respectively. ROC analysis of the combined MMP-7 and FGA data yielded an AUC of 0.742 (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A).</p><p id="Par18">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Assessment of baseline levels of MMP-7 and FGA as predictors of LDA at 3 months. Receiver operating characteristic curve analysis and area under the curve (<bold>A</bold>) of MMP-7 (light gray line), FGA (dark gray line) and the combination of MMP-7 and FGA (black line); proportion of patients who achieved a low DAS28 at 3 months among the groups dichotomized by MMP-7 (<bold>B</bold>), FGA (<bold>C</bold>) or the combination of MMP-7 and FGA (<bold>D</bold>)</p></caption><graphic xlink:href="41927_2025_509_Fig1_HTML" id="d33e676"/></fig>
</p><p id="Par20">60% of patients with low MMP-7 levels at baseline (<italic>N</italic>&#x02009;=&#x02009;50) achieved LDA after 3 months of MTX monotherapy, whereas only 24% of those with high MMP-7 levels (<italic>N</italic>&#x02009;=&#x02009;85) achieved LDA (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B). Similar proportions were observed when patients with low (<italic>N</italic>&#x02009;=&#x02009;57) versus high (<italic>N</italic>&#x02009;=&#x02009;78) FGA levels were compared (58% versus 22%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>C).</p><p id="Par21">79% (<italic>n</italic>&#x02009;=&#x02009;23/29) of patients with low levels of both MMP-7 and FGA at baseline achieved LDA at 3 months, whereas only 18% (<italic>n</italic>&#x02009;=&#x02009;10/57) of patients with high levels of both proteins did so (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>D). Patients with low levels of MMP-7 and high levels of FGA (<italic>n</italic>&#x02009;=&#x02009;21), as well as those with high levels of MMP-7 and low levels of FGA (<italic>n</italic>&#x02009;=&#x02009;28), did not differ significantly in terms of the proportion of patients who achieved LDA: 33% and 36%, respectively (<italic>p</italic>&#x02009;=&#x02009;0.862, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>D). Similar results were observed for good EULAR response as a treatment outcome (60% versus 22%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001; 58% versus 20%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001; and 79% versus 15%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, respectively; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A, B and C). These comparisons of proportions with LDA or EULAR good responses within each stratum of the baseline DAS28 (moderate or high) resulted in a similar pattern (Supplementary Figure <xref rid="MOESM2" ref-type="media">S2</xref>).</p><p id="Par22">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Proportion of MTX responders among patients with low versus high levels of serum biomarkers. Proportion of patients with good EULAR response among those dichotomized by MMP-7 (<bold>A</bold>), FGA (<bold>B</bold>) or a combination of MMP-7 and FGA (<bold>C</bold>)</p></caption><graphic xlink:href="41927_2025_509_Fig2_HTML" id="d33e766"/></fig>
</p></sec></sec><sec id="Sec4"><title>Discussion</title><p id="Par23">In this post hoc analysis of eRA patients who participated in the SWEFOT trial, we studied a panel of 177 serum proteins at baseline, prior to the initiation of DMARDs, to predict the response to subsequent 3 months of MTX monotherapy. Among the strengths of this trial is that the patients were DMARD treatment na&#x000ef;ve (only allowing the use of low-dose corticosteroids if the dose had been stable for &#x0003e;&#x02009;4 weeks), with few inclusion and exclusion criteria, thereby representing a typical early RA population [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. </p><p id="Par24">We found that two proteins (MMP-7 and FGA) were associated with the achievement of good LDA or EULAR responses at 3 months, with clinically meaningful differences between the groups. Unlike other MMPs, MMP-7 has a broader proteolytic function. Kazantseva et al. demonstrated that higher expression of MMP-7 was associated with a specific polymorphism in the MMP-7 promoter and was greater in extra-articular subcutaneous rheumatoid nodules than in the synovium [<xref ref-type="bibr" rid="CR16">16</xref>]. They also demonstrated that in nodules of patients with higher expression of MMP-7, there was more fibrinoid collagen and infiltrated neutrophils than in nodules with lower expression of MMP-7.</p><p id="Par25">Fibrinogen accumulates in the inflamed joints of patients with RA. Its citrullination (both &#x003b1;- and &#x003b2;-chains) is a target for autoantibodies [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>], which are associated with more destructive disease. Since MTX is not known for its ability to reduce citrullination or influence fibrinogen levels, patients with lower FGA levels at baseline are presumably more likely to respond, as evidenced by the results.</p><p id="Par26">We could not find any published data concerning the ability of MMP-7 or FGA to predict the clinical response to MTX. Therefore, validation of these results is highly relevant.</p><p id="Par27">The strengths of this study were the inclusion criteria of the SWEFOT trial, which allowed us to assess MTX effectiveness in DMARD-na&#x000ef;ve eRA patients. Another strength is the large number of proteins screened, the choice of which was based on ongoing inflammatory and autoimmunity studies. One limitation, but also a strength, was that patients were selected to have similar RF-positivity in responders and non-responders groups. The baseline CRP, ESR and VAS pain differed at baseline between the two groups which might contribute to the differences between the groups. However, these factors might also be part in predicting the response.</p><p id="Par28">There were several limitations as well. The cut-offs for MMP-7 and FGA that are based on the MFI need to be validated on the basis of concentration. Next, the SWEFOT trial was not designed to investigate these biomarkers for the prediction of the response to MTX. Therefore, the selected patients for this study, which were selected with the aim of achieving an even distribution of autoantibody positivity among men and women since RF positivity might influence the detection of certain proteins, were not representative of the entire SWEFOT; consequently, it is not possible to interpret previously published predictors [<xref ref-type="bibr" rid="CR6">6</xref>] in this subset.</p></sec><sec id="Sec5"><title>Conclusions</title><p id="Par29">In summary, two of the 177 proteins measured prior to DMARD therapy in early RA, MMP-7 and FGA, were associated with the response to MTX at 3 months. A greater proportion of patients with low levels of these proteins were responders than those with high levels of MMP-7 and FGA. The differences were clinically meaningful, and the method, after minor modifications, is feasible in a routine clinical setting. Validation of these results in another eRA cohort using the same detecting antibodies is now an important first validation step toward eventual implementation to optimize early RA treatment.</p></sec><sec id="Sec6" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41927_2025_509_MOESM1_ESM.tif"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41927_2025_509_MOESM2_ESM.tif"><caption><p>Supplementary Material 2</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41927_2025_509_MOESM3_ESM.docx"><caption><p>Supplementary Material 3</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="41927_2025_509_MOESM4_ESM.docx"><caption><p>Supplementary Material 4</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to thank all participants of the SWEFOT trial (Trial registration number: NCT00764725), as well as the study nurses, coinvestigators and colleagues, who made the study possible.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>KH analysed and interpreted the proteomic data in relation to patient data and clinical outcomes and was a major contributor to the writing of the manuscript. CH and LL designed and performed the proteomic analysis and interpreted the results. SS and PN reviewed the clinical and proteomic data, respectively. RvV, P-JJ and HI designed the study and interpreted the results. All the authors were part of the writing of the manuscript and read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by Karolinska Institute.</p><p>This work was supported in part by a grant from the Swedish Rheumatism Association, the Swedish research council, Stiftelsen Konung Gustaf V: s 80-&#x000e5;rsfond, Xunta de Galicia (IN606B-2016/2005), Contrato Sara Borrell (CD19/00229) Fondo de Investigaci&#x000f3;n Sanitaria, ISCIII.and funds from Karolinska Institutet and Stockholm County Council (ALF funds).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par30">The SWFOT trial was conducted in accordance with the Declaration of Helsinki and by the regional ethics committees of all participating units [Karolinska Institutet 02-211, Orebro 2002/202 500:16, Umea 2002, Linkoping 02-186, Uppsala Ups 02-241, Goteborg Gbg O 282-01, M 088&#x02009;&#x02212;&#x02009;02, Lund LU 398-01, and Stockholm Central Ethical Review Board (EPN) 2005/1361, 2006/248-3]. All patients provided written informed consent before enrolment in the trial.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par31">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par32">R.F.vV. received research support and grants from AbbVie, BMS, GSK, Pfizer, UCB; and Consultancy, honoraria: AbbVie, AstraZeneca, Biotest, BMS, Celgene, GSK, Janssen, Lilly, Novartis, Pfizer, UCB. S.S. is a part-time employee of deCODE genetics unrelated to this work. All the other authors declare that they have no conflicts of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Smolen</surname><given-names>JS</given-names></name><name><surname>Aletaha</surname><given-names>D</given-names></name><name><surname>Barton</surname><given-names>A</given-names></name><name><surname>Burmester</surname><given-names>GR</given-names></name><name><surname>Emery</surname><given-names>P</given-names></name><name><surname>Firestein</surname><given-names>GS</given-names></name><etal/></person-group><article-title>Rheumatoid arthritis</article-title><source>Nat Reviews Disease Primers</source><year>2018</year><volume>4</volume><issue>1</issue><fpage>18001</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2018.1</pub-id><pub-id pub-id-type="pmid">29417936</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Reviews Disease Primers. 2018;4(1):18001.<pub-id pub-id-type="pmid">29417936</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis care &#x00026; research (2010). 2016;68(1):1&#x02013;25.</mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Smolen</surname><given-names>JS</given-names></name><name><surname>Landew&#x000e9;</surname><given-names>R</given-names></name><name><surname>Bijlsma</surname><given-names>J</given-names></name><name><surname>Burmester</surname><given-names>G</given-names></name><name><surname>Chatzidionysiou</surname><given-names>K</given-names></name><name><surname>Dougados</surname><given-names>M</given-names></name><etal/></person-group><article-title>EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update</article-title><source>Ann Rheum Dis</source><year>2017</year><volume>76</volume><issue>6</issue><fpage>960</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2016-210715</pub-id><pub-id pub-id-type="pmid">28264816</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Smolen JS, Landew&#x000e9; R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960&#x02013;77.<pub-id pub-id-type="pmid">28264816</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>van Vollenhoven</surname><given-names>RF</given-names></name><name><surname>Ernestam</surname><given-names>S</given-names></name><name><surname>Geborek</surname><given-names>P</given-names></name><name><surname>Petersson</surname><given-names>IF</given-names></name><name><surname>C&#x000f6;ster</surname><given-names>L</given-names></name><name><surname>Waltbrand</surname><given-names>E</given-names></name><etal/></person-group><article-title>Addition of Infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial</article-title><source>Lancet</source><year>2009</year><volume>374</volume><issue>9688</issue><fpage>459</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)60944-2</pub-id><pub-id pub-id-type="pmid">19665644</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, C&#x000f6;ster L, Waltbrand E, et al. Addition of Infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009;374(9688):459&#x02013;66.<pub-id pub-id-type="pmid">19665644</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Dell</surname><given-names>JR</given-names></name><name><surname>Haire</surname><given-names>CE</given-names></name><name><surname>Erikson</surname><given-names>N</given-names></name><name><surname>Drymalski</surname><given-names>W</given-names></name><name><surname>Palmer</surname><given-names>W</given-names></name><name><surname>Eckhoff</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications</article-title><source>N Engl J Med</source><year>1996</year><volume>334</volume><issue>20</issue><fpage>1287</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1056/NEJM199605163342002</pub-id><pub-id pub-id-type="pmid">8609945</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">O&#x02019;Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 1996;334(20):1287&#x02013;91.<pub-id pub-id-type="pmid">8609945</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Saevarsdottir</surname><given-names>S</given-names></name><name><surname>Wallin</surname><given-names>H</given-names></name><name><surname>Seddighzadeh</surname><given-names>M</given-names></name><name><surname>Ernestam</surname><given-names>S</given-names></name><name><surname>Geborek</surname><given-names>P</given-names></name><name><surname>Petersson</surname><given-names>IF</given-names></name><etal/></person-group><article-title>Predictors of response to methotrexate in early DMARD Na&#x000ef;ve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial</article-title><source>Ann Rheum Dis</source><year>2010</year><volume>70</volume><issue>3</issue><fpage>469</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1136/ard.2010.139212</pub-id><pub-id pub-id-type="pmid">21149498</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Saevarsdottir S, Wallin H, Seddighzadeh M, Ernestam S, Geborek P, Petersson IF, et al. Predictors of response to methotrexate in early DMARD Na&#x000ef;ve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis. 2010;70(3):469&#x02013;75.<pub-id pub-id-type="pmid">21149498</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Wessels</surname><given-names>JAM</given-names></name><name><surname>van der Kooij</surname><given-names>SM</given-names></name><name><surname>le Cessie</surname><given-names>S</given-names></name><name><surname>Kievit</surname><given-names>W</given-names></name><name><surname>Barerra</surname><given-names>P</given-names></name><name><surname>Allaart</surname><given-names>CF</given-names></name><etal/></person-group><article-title>A clinical Pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis</article-title><source>Arthr Rhuem</source><year>2007</year><volume>56</volume><issue>6</issue><fpage>1765</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1002/art.22640</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Wessels JAM, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF, et al. A clinical Pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthr Rhuem. 2007;56(6):1765&#x02013;75.</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Saevarsdottir</surname><given-names>S</given-names></name><name><surname>Wedr&#x000e9;n</surname><given-names>S</given-names></name><name><surname>Seddighzadeh</surname><given-names>M</given-names></name><name><surname>Bengtsson</surname><given-names>C</given-names></name><name><surname>Wesley</surname><given-names>A</given-names></name><name><surname>Lindblad</surname><given-names>S</given-names></name><etal/></person-group><article-title>Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the epidemiological investigation of rheumatoid arthritis and the Swedish rheumatology reg</article-title><source>Arthr Rhuem</source><year>2010</year><volume>63</volume><issue>1</issue><fpage>26</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1002/art.27758</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Saevarsdottir S, Wedr&#x000e9;n S, Seddighzadeh M, Bengtsson C, Wesley A, Lindblad S, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the epidemiological investigation of rheumatoid arthritis and the Swedish rheumatology reg. Arthr Rhuem. 2010;63(1):26&#x02013;36.</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>van Dongen</surname><given-names>H</given-names></name><name><surname>van Aken</surname><given-names>J</given-names></name><name><surname>Lard</surname><given-names>LR</given-names></name><name><surname>Visser</surname><given-names>K</given-names></name><name><surname>Ronday</surname><given-names>HK</given-names></name><name><surname>Hulsmans</surname><given-names>HMJ</given-names></name><etal/></person-group><article-title>Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial</article-title><source>Arthr Rhuem</source><year>2007</year><volume>56</volume><issue>5</issue><fpage>1424</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1002/art.22525</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HMJ, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial. Arthr Rhuem. 2007;56(5):1424&#x02013;32.</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>K</given-names></name><name><surname>Jiang</surname><given-names>P</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Biomarkers to predict DMARDs efficacy and adverse effect in rheumatoid arthritis</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>865267</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.865267</pub-id><pub-id pub-id-type="pmid">35418971</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Wei K, Jiang P, Zhao J, Jin Y, Zhang R, Chang C, et al. Biomarkers to predict DMARDs efficacy and adverse effect in rheumatoid arthritis. Front Immunol. 2022;13:865267.<pub-id pub-id-type="pmid">35418971</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Palmowski</surname><given-names>A</given-names></name><name><surname>Strehl</surname><given-names>C</given-names></name><name><surname>Pfeiffenberger</surname><given-names>M</given-names></name><name><surname>H&#x000e4;upl</surname><given-names>T</given-names></name><name><surname>Schad</surname><given-names>M</given-names></name><name><surname>Kallarackal</surname><given-names>J</given-names></name><etal/></person-group><article-title>Identification of gene expression biomarkers to predict clinical response to methotrexate in patients with rheumatoid arthritis</article-title><source>Clin Rheumatol</source><year>2024</year><volume>43</volume><issue>1</issue><fpage>511</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s10067-023-06814-2</pub-id><pub-id pub-id-type="pmid">37978145</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Palmowski A, Strehl C, Pfeiffenberger M, H&#x000e4;upl T, Schad M, Kallarackal J, et al. Identification of gene expression biomarkers to predict clinical response to methotrexate in patients with rheumatoid arthritis. Clin Rheumatol. 2024;43(1):511&#x02013;9.<pub-id pub-id-type="pmid">37978145</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>van Gestel</surname><given-names>AM</given-names></name><name><surname>Haagsma</surname><given-names>CJ</given-names></name><name><surname>van Riel</surname><given-names>PLCM</given-names></name></person-group><article-title>Validation of rheumatoid arthritis improvement criteria that include simplified joint counts</article-title><source>Arthr Rhuem</source><year>1998</year><volume>41</volume><issue>10</issue><fpage>1845</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1002/1529-0131(199810)41:10&#x0003c;1845::AID-ART17&#x0003e;3.0.CO;2-K</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">van Gestel AM, Haagsma CJ, van Riel PLCM. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthr Rhuem. 1998;41(10):1845&#x02013;50.</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Schwenk</surname><given-names>JM</given-names></name><name><surname>Gry</surname><given-names>M</given-names></name><name><surname>Rimini</surname><given-names>R</given-names></name><name><surname>Uhl&#x000e9;n</surname><given-names>M</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name></person-group><article-title>Antibody suspension bead arrays within serum proteomics</article-title><source>J Proteome Res</source><year>2008</year><volume>7</volume><issue>8</issue><fpage>3168</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1021/pr700890b</pub-id><pub-id pub-id-type="pmid">18588325</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Schwenk JM, Gry M, Rimini R, Uhl&#x000e9;n M, Nilsson P. Antibody suspension bead arrays within serum proteomics. J Proteome Res. 2008;7(8):3168&#x02013;79.<pub-id pub-id-type="pmid">18588325</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Drobin K, Nilsson P, Schwenk JM. Highly multiplexed antibody suspension bead arrays for plasma protein profiling. Methods in Molecular Biology. Springer New York; 2013. pp. 137&#x02013;45.</mixed-citation></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>van Vollenhoven</surname><given-names>RF</given-names></name><name><surname>Geborek</surname><given-names>P</given-names></name><name><surname>Forslind</surname><given-names>K</given-names></name><name><surname>Albertsson</surname><given-names>K</given-names></name><name><surname>Ernestam</surname><given-names>S</given-names></name><name><surname>Petersson</surname><given-names>IF</given-names></name><etal/></person-group><article-title>Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial</article-title><source>Lancet</source><year>2012</year><volume>379</volume><issue>9827</issue><fpage>1712</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)60027-0</pub-id><pub-id pub-id-type="pmid">22464340</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012;379(9827):1712&#x02013;20.<pub-id pub-id-type="pmid">22464340</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Kazantseva</surname><given-names>MG</given-names></name><name><surname>Hung</surname><given-names>NA</given-names></name><name><surname>Highton</surname><given-names>J</given-names></name><name><surname>Hessian</surname><given-names>PA</given-names></name></person-group><article-title>MMP expression in rheumatoid inflammation: the rs11568818 polymorphism is associated with MMP-7 expression at an extra-articular site</article-title><source>Genes Immun</source><year>2013</year><volume>14</volume><issue>3</issue><fpage>162</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/gene.2012.65</pub-id><pub-id pub-id-type="pmid">23343931</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Kazantseva MG, Hung NA, Highton J, Hessian PA. MMP expression in rheumatoid inflammation: the rs11568818 polymorphism is associated with MMP-7 expression at an extra-articular site. Genes Immun. 2013;14(3):162&#x02013;9.<pub-id pub-id-type="pmid">23343931</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Fernandes-Cerqueira C, Ossipova E, Gunasekera S, Hansson M, Mathsson L, Catrina AI et al. Targeting of anti-citrullinated protein/peptide antibodies in rheumatoid arthritis using peptides mimicking endogenously citrullinated fibrinogen antigens. Arthritis Res Therapy. 2015;17(1).</mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Hermansson M, Artemenko K, Ossipova E, Eriksson H, Lengqvist J, Makrygiannakis D et al. Mass spectrometric analysis of rheumatoid arthritic synovial tissue identifies specific citrullination sites on fibrinogen. PROTEOMICS - CLINICAL APPLICATIONS. 2010:NA-NA.</mixed-citation></ref></ref-list></back></article>